Guidance
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards, technical committees and working groups
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
MiE WP26-27 Consultation - Potential Research Topics only
MiE WP26-27 Consultation and context pointers
MiE WP26-27 Consultation with pointers to WP25-27 consultation
MiE KPIs
Relevant (future) calls
EU-Programme-Call
NACE code
EFFRA Organisations - members
EFFRA WG pointers
Pathways
Pathways
Projects
Projects
Resources
Resources
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
Structured Wiki
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2014-01-two-stage
IMI2-2014-01-01 Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)
H2020-JTI-IMI2-2014-02-single-stage
IMI2-2014-02-01 Vaccine development Phase I, II, and III
IMI2-2014-02-04 Deployment and compliance of vaccination regimens
IMI2-2014-02-05 Rapid diagnostic tests
H2020-JTI-IMI2-2015-03-two-stage
IMI2-2015-03-01 Remote Assessment of Disease and Relapse - CNS
IMI2-2015-03-02 Assessing Risk and Progression of Prediabetes and Type 2 Diabetes to Enable Disease Modification
IMI2-2015-03-03 Linking Clinical Neuropsychiatry and Quantitative Neurobiology
IMI2-2015-03-05 Pertussis vaccination research
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-01 Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and Health Technology Assessment bodie
IMI2-2015-05-02 Diabetic Kidney Disease Biomarkers (DKD-BM)
IMI2-2015-05-03 Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33
IMI2-2015-05-04 Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
IMI2-2015-05-05 Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: Phased expansion study
IMI2-2015-05-06 From ApoE biology to validated Alzheimer’s disease targets
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-01 Development of Quantitative System Toxicology (QST) approaches to improve the understanding of the safety of new medicines
IMI2-2015-06-02 Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences
IMI2-2015-06-03 Real World Outcomes Across the AD Spectrum (ROADS) to Better Care
IMI2-2015-06-04 Development of an outcomes-focused data platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-01 VALIDATION OF TRANSLATIONAL IMAGING METHODS IN DRUG SAFETY ASSESSMENT (TRISTAN)
IMI2-2015-07-02 IDENTIFICATION OF DRUGGABLE TARGETS MODULATING MISFOLDED PROTEINS IN ALZHEIMER’S AND PARKINSON’S DISEASES
IMI2-2015-07-03 PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN
IMI2-2015-07-04 DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER
IMI2-2015-07-06 COORDINATION AND SUPPORT ACTIONS (CSA) FOR THE BIG DATA FOR BETTER OUTCOMES PROGRAMME
IMI2-2015-07-07 INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS
H2020-JTI-IMI2-2015-08-single-stage
IMI2-2015-08-01 Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-01 ADDRESSING THE CLINICAL BURDEN OF CLOSTRIDIUM DIFFICILE INFECTION (CDI): EVALUATION OF THE BURDEN, CURRENT PRACTICES AND SET-UP OF A EUROPEAN RESEARCH PLATFORM (PART OF THE IMI NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME)
IMI2-2016-09-02 DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES
IMI2-2016-09-03 DATA QUALITY IN PRECLINICAL RESEARCH AND DEVELOPMENT
IMI2-2016-09-04 NEXT GENERATION OF ELECTRONIC TRANSLATIONAL SAFETY – NEXGETS
IMI2-2016-09-05 IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ACROSS THE SPECTRUM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
IMI2-2016-09-06 JOINT INFLUENZA VACCINE EFFECTIVENESS STUDIES
H2020-JTI-IMI2-2016-10-two-stage
IMI2-2016-10-01 Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
IMI2-2016-10-02 How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer
IMI2-2016-10-03 Improving the care of patients suffering from acute or chronic pain
IMI2-2016-10-04 Creation of a pan-European Paediatric Clinical Trials Network
IMI2-2016-10-05 Biomanufacturing 2020: Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
IMI2-2016-10-06 Unlocking the Solute Carrier Gene-Family for Effective New Therapies (Unlock SLCs)
IMI2-2016-10-07 Patient perspectives in medicines lifecycle
IMI2-2016-10-08 Personalised medicine approaches in autism spectrum disorders
H2020-JTI-IMI2-2017-11-single-stage
IMI2-2017-11-01 Exploitation of IMI project results
H2020-JTI-IMI2-2017-12-two-stage
IMI2-2017-12-01 Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s Disease (RADAR-AD)
IMI2-2017-12-02 FAIRification of IMI and EFPIA data
IMI2-2017-12-03 Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
IMI2-2017-12-04 European Health Data Network (EHDN)
IMI2-2017-12-05 Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
IMI2-2017-12-06 Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases
IMI2-2017-12-07 European Screening Centre: unique library for attractive biology (ESCulab)
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-01 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease
IMI2-2017-13-03 The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration
IMI2-2017-13-05 Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
IMI2-2017-13-06 A sustainable European induced pluripotent stem cell platform
IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling
IMI2-2017-13-09 ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
IMI2-2017-13-11 Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
IMI2-2017-13-15 Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases
H2020-JTI-IMI2-2018-14-two-stage
IMI2-2018-14-01 Targeted immune intervention for the management of non-response and relapse
IMI2-2018-14-02 Non-invasive clinical molecular imaging of immune cells
IMI2-2018-14-03 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
IMI2-2018-14-04 Centre Of Excellence – Remote Decentralised Clinical Trials
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-01 Integrated research platforms enabling patient-centric drug development
IMI2-2018-15-02 Blockchain Enabled Healthcare
IMI2-2018-15-03 Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases
IMI2-2018-15-04 Emerging translational safety technologies and tools for interrogating human immuno-biology
IMI2-2018-15-06 Digital endpoints in neurodegenerative and immune-mediated diseases
IMI2-2018-15-07 AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
IMI2-2018-15-08 AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
H2020-JTI-IMI2-2018-16-single-stage
IMI2-2018-16-01 Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
IMI2-2018-16-02 Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
IMI2-2018-16-04 Determination of gepotidacin levels in tonsils and prostatic tissue
IMI2-2018-16-06 Functional Ethionamide boosters: a novel combination for tuberculosis therapy
IMI2-2018-16-07 Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
H2020-JTI-IMI2-2019-17-two-stage
IMI2-2019-17-01 Optimising future obesity treatment
IMI2-2019-17-02 Open access chemogenomics library and chemical probes for the druggable genome
IMI2-2019-17-03 Intelligent prediction and identification of environmental risks posed by human medicinal products
H2020-JTI-IMI2-2019-18-two-stage
IMI2-2019-18-01 Central repository of digital pathology slides to support the development of artificial intelligence tools
IMI2-2019-18-02 Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes
IMI2-2019-18-03 Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project
IMI2-2019-18-04 Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
IMI2-2019-18-05 Accelerating research & innovation for advanced therapy medicinal products
IMI2-2019-18-06 Supporting the development of engineered T cells
H2020-JTI-IMI2-2019-19-single-stage
IMI2-2019-19-01 Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
H2020-JTI-IMI2-2020-21-single-stage
IMI2-2020-21-01